Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $6.7352W HIGH $23.19
Volume
567.53 K
Value Traded
12.00 M
Short % Float
19.85%
-3.18%Week
-23.87%1 Month
-13.09%3 Month
+8.98%6 Month
-49.19%5 Year
-67.05%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
999.43 M
EPS (TTM)
-3.18
P/E Ratio
-
Ent. Value
664.89 M
Total Shares
64.35 M
Float Shares
48.50 M
Insiders
24.87%
Institutions
88.23%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
CGEM Catalyst Timeline
Dated clinical, regulatory and corporate events for Cullinan Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Cullinan Therapeutics, Inc.
326Total events
21Upcoming
75Tier-1 (high impact)
2020 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲First Patient DosedCLN-049Trial
First patient dosed in pivotal Phase 2 study of CLN-049 in relapsed/refractory AML
relapsed/refractory acute myeloid leukemia (AML)source ↗
●NDA SubmissionzipalertinibFiledRegulatory Filing
NDA submission initiated for zipalertinib plus chemotherapy in first-line EGFR ex20ins NSCLC under RTOR
previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutationssource ↗
●R&D DayPresentation
Cullinan to participate in fireside chat at Stifel 2026 Virtual Immunology and Inflammation Forum
●R&D DayPresentation
Cullinan Therapeutics virtual analyst and investor event to discuss REZILIENT3 interim analysis results
◆Interim AnalysiszipalertinibFiledTrial
Planned interim analysis of Phase 3 REZILIENT3 of zipalertinib plus chemotherapy
lung cancersource ↗
●Oral PresentationzipalertinibFiledPresentation
Zipalertinib plus chemotherapy Phase 3 REZILIENT3 data presented at IASLC 2026 WCLC Presidential Symposium 2
lung cancersource ↗
▲Topline ReadoutzipalertinibFiledClinical Data
REZILIENT3 results presented at IASLC 2026 WCLC Presidential Symposium 2
first-line EGFR exon 20 insertion mutation non-small cell lung cancersource ↗
▲Late-BreakerzipalertinibFiledPresentation
Late-breaking REZILIENT3 results selected for Presidential Symposium 2 at WCLC 2026
first-line EGFR exon 20 insertion mutation non-small cell lung cancersource ↗
▲Oral PresentationzipalertinibFiledPresentation
REZILIENT3 Phase 3 data presented at the International conference
first-line EGFR exon 20 insertion mutation-positive non-small cell lung cancersource ↗
▲Topline ReadoutzipalertinibFiledClinical Data
Zipalertinib plus chemotherapy demonstrates 6-month median PFS benefit in REZILIENT3 Phase 3 trial
first-line EGFR exon 20 insertion mutation-positive non-small cell lung cancersource ↗
▲Primary Endpoint MetzipalertinibFiledClinical Data
REZILIENT3 met primary endpoint of PFS at planned interim analysis
first-line EGFR exon 20 insertion mutation non-small cell lung cancersource ↗
▲Interim AnalysiszipalertinibFiledTrial
Pre-planned interim efficacy analysis of REZILIENT3 after 122 PFS events
first-line EGFR exon 20 insertion mutation non-small cell lung cancersource ↗
●Interim Efficacy DatazipalertinibFiledClinical Data
Interim overall survival analysis (30% event maturity) from REZILIENT3
first-line EGFR exon 20 insertion mutation non-small cell lung cancersource ↗
▲Primary Endpoint MetzipalertinibFiledClinical Data
REZILIENT3 interim analysis met primary endpoint of progression-free survival
first-line EGFR exon 20 insertion mutation NSCLCsource ↗
▲Interim AnalysiszipalertinibFiledTrial
Planned interim analysis of REZILIENT3 met primary endpoint of progression-free survival
first line EGFR exon 20 insertion mutation NSCLCsource ↗
▲Primary Endpoint MetzipalertinibFiledClinical Data
REZILIENT3 meets primary endpoint of progression-free survival
first-line EGFR Exon 20 insertion mutation non-small cell lung cancersource ↗
◆Interim AnalysiszipalertinibFiledTrial
Planned interim analysis of REZILIENT3 trial
first-line EGFR Exon 20 insertion mutation non-small cell lung cancersource ↗
▲End Of Phase 1 MeetingCLN-049FDA Meeting
Positive End-of-Phase 1 meeting with FDA for CLN-049
acute myeloid leukemia (AML)source ↗
◆Trial InitiationCLN-049Trial
Plan to initiate potentially registrational Phase 2 study for CLN-049 in R/R AML
relapsed/refractory AMLsource ↗
▲End Of Phase 1 MeetingCLN-049FDA Meeting
Positive End-of-Phase 1 meeting with FDA for CLN-049
acute myeloid leukemiasource ↗
◆Topline ReadoutCLN-978Clinical Data
Plan to share additional multi-dose regimen data for CLN-978 in RA
rheumatoid arthritissource ↗
◆Topline ReadoutCLN-978Clinical Data
Initial data from first multi-dose cohort of RA study
rheumatoid arthritissource ↗
◆Topline ReadoutVelinotamigClinical Data
Initial data from first multi-dose cohort of velinotamig study in China
autoimmune diseases driven by long-lived plasma cellssource ↗
◆Full ResultsCLN-978Clinical Data
Data from first RA multi-dose regimen cohort for CLN-978 to be shared at Immunology Day
rheumatoid arthritissource ↗
◆Full ResultsVelinotamigClinical Data
Initial clinical data for velinotamig to be shared at Immunology Day
▲Poster PresentationCLN-978Presentation
Initial clinical data for CLN-978 in SLE presented at EULAR 2026
systemic lupus erythematosussource ↗
◆Oral PresentationCLN-978Presentation
Single target dose escalation data in SLE and RA reported at EULAR 2026 Congress
systemic lupus erythematosus; rheumatoid arthritissource ↗
▲Oral PresentationCLN-978Presentation
Presented initial single target dose and multi-dose regimen data for CLN-978 in RA at EULAR 2026 and Immunology Day
rheumatoid arthritissource ↗
▲Oral PresentationVelinotamigPresentation
Shared encouraging early clinical observations for velinotamig at Immunology Day
autoimmune diseasessource ↗
▲Orphan Drug DesignationCLN-049Designation
FDA grants Orphan Drug Designation for CLN-049 in R/R AML
relapsed/refractory acute myeloid leukemiasource ↗
▲FDA Filing AcceptedzipalertinibFiledRegulatory Filing
FDA accepts NDA for zipalertinib
locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutationssource ↗
▲FDA Filing AcceptedzipalertinibFiledRegulatory Filing
FDA accepted NDA for zipalertinib
EGFR ex20ins NSCLCsource ↗
◆Oral PresentationPresentation
Participation in upcoming investor conferences with fireside chats
▲Enrollment CompletezipalertinibFiledTrial
Taiho completed enrollment of REZILIENT3 study
EGFR ex20ins NSCLCsource ↗
●NDA SubmissionzipalertinibFiledRegulatory Filing
Rolling NDA submission to FDA for zipalertinib in 2L EGFR ex20ins NSCLC completed
EGFR ex20ins NSCLC (2L+)source ↗
◆Enrollment CompletezipalertinibFiledTrial
Enrollment completion expected for REZILIENT3 in first half of 2026
EGFR ex20ins NSCLC (frontline)source ↗
▲Oral PresentationzipalertinibFiledPresentation
REZILIENT3 results presented at IASLC 2026 World Conference on Lung Cancer Presidential Symposium
first-line EGFR exon 20 insertion mutation NSCLCsource ↗
▲Oral PresentationCLN-049Presentation
Oral presentation of updated clinical data for CLN-049 at 67th ASH Annual Meeting
relapsed/refractory acute myeloid leukemia (R/R AML)source ↗
●R&D DayPresentation
Cullinan Therapeutics in-person investor event discussing CLN-049 data at ASH 2025
▲Fast Track DesignationCLN-049Designation
CLN-049 granted Fast Track designation by U.S. FDA for treatment of R/R AML
relapsed/refractory acute myeloid leukemia (R/R AML)source ↗
▲Fast Track DesignationCLN-049Designation
FDA grants Fast Track designation for CLN-049 in R/R AML
relapsed/refractory acute myeloid leukemiasource ↗
◆Trial InitiationVelinotamigTrial
Genrix plans to initiate Phase 1 study in China in autoimmune diseases
autoimmune diseasessource ↗
●Timing GuidancezipalertinibFiledPresentation
Taiho plans to submit NDA for zipalertinib in relapsed EGFR ex20ins NSCLC
relapsed EGFR ex20ins NSCLCsource ↗
Past FDA Catalysts and PDUFA Decisions
How CGEM actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-13 | zipalertinib plus chemotherapy | Phase 3 data presentation | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C49 / 100
Pipeline Score
$390M
Pipeline Value
Overvalued
Valuation Signal
5
Drugs Scored
0.4x
rNPV / MCap
Top 19%
Micro Cap(rank 126 of 657)
Percentile Rank
Cullinan Therapeutics, Inc. carries a moderate pipeline score (49/100), with $975M risk-adjusted pipeline value, led by CLN-619 in Multiple Myeloma (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CLN-619 Small moleculeNCT05117476 | Advanced Solid Tumor | Phase 1 | ACTIVE NOT_RECRUITING | 440 | Jun 1, 2026 |
Clinical Trial Results
Readouts, endpoints and source filings for every CGEM program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| zipalertinib Breakthrough | non-small cell lung cancer | Phase 3 | 2026-09-13 | 6-Month Median Progression-Free Survival BenefitRead More | Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung CancerRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Michaelson JenniferOfficer (Chief Scientific Officer) | Option | 4,000 166,844 held | $4.30 | 09/08/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CGEM
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| BIOIMPACT CAPITAL LLC | 10.8 % (28.6 %) | 177.21 M | 9.73 M | 27.24% ( 2.08 M) |
CGEM Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-01-15 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CGEM ranks across every disease it competes in
Competitive Position is a premium feature
See how CGEM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCGEM News
CGEM▲ +0.4%today
Cullinan Therapeutics Announces First Patient Dosed in Planned Registrational Phase 2 Study of CLN-049 in Relapsed/Refractory Acute Myeloid Leukemia
Cullinan Therapeutics has announced the dosing of the first patient in its pivotal Phase 2 study of CLN-049, aimed at treating relapsed/refractory acute myeloid leukemia (AML). This investigational FLT3 T cell engager is designed to target FLT3-expressing leukemia cells, providing a new treatment avenue for patients with limited options. The study follows a successful End-of-Phase 1 meeting with the FDA and includes an exploratory cohort for TP53-mutated AML.
Read more →CGEM▲ +6.7%on this news
New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program
Cullinan Therapeutics has initiated a New Drug Application for zipalertinib in combination with chemotherapy for treating EGFR exon 20 insertion mutation non-small cell lung cancer (NSCLC). This submission follows the promising results from the Phase 3 REZILIENT3 study, which showed significant improvement in progression-free survival. The NDA is being reviewed under the FDA's Real-Time Oncology Review program, with completion expected by late 2026.
Read more →CGEM▼ -8.5%on this news
Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio
Cullinan Therapeutics has outlined significant milestones for Q4 2026, focusing on its T cell engager portfolio in immunology and oncology. Key updates include multi-dose regimen data for CLN-978 and velinotamig, as well as CLN-049's Phase 1 study results. The company anticipates sharing comprehensive data at the ACR Convergence 2026 event and progressing towards a Phase 2 study for CLN-049.
Read more →CGEMCullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum
Cullinan Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in the Stifel 2026 Virtual Immunology and Inflammation Forum. CEO Nadim Ahmed and CMO Jeffrey Jones will engage in a fireside chat on September 24, 2026. The event highlights Cullinan's commitment to developing innovative T cell engagers for autoimmune diseases and cancer.
Read more →CGEMCullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer
Cullinan Therapeutics is hosting a virtual analyst and investor event to discuss the interim analysis results of the Phase 3 REZILIENT3 trial of zipalertinib plus chemotherapy. The results will be presented at the IASLC 2026 World Conference on Lung Cancer. Key executives will participate in the event, which will be available via live webcast.
Read more →CGEMZipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics announced positive results from the Phase 3 REZILIENT3 trial. The trial evaluated zipalertinib combined with chemotherapy against chemotherapy alone for patients with EGFR exon 20 insertion mutation-positive non-small cell lung cancer. The findings indicate a significant median progression-free survival benefit for the combination treatment.
Read more →CGEMCullinan Therapeutics to Host Virtual Analyst and Investor Event to Showcase Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer
Cullinan Therapeutics will host a virtual analyst and investor event on September 14, 2026, to discuss the interim analysis results of the Phase 3 REZILIENT3 trial of zipalertinib plus chemotherapy for NSCLC. The trial met its primary endpoint of progression-free survival, and results will be presented at the IASLC 2026 World Conference on Lung Cancer. Key executives will participate in the event.
Read more →CGEMZipalertinib Plus Chemotherapy First-Line Phase 3 REZILIENT3 Trial Data Selected for Presidential Symposium Presentation at the IASLC 2026 World Conference on Lung Cancer
The Phase 3 REZILIENT3 trial results for Zipalertinib combined with chemotherapy have been selected for presentation at the IASLC 2026 World Conference on Lung Cancer. The interim analysis indicates that the trial successfully met its primary endpoint of progression-free survival in patients with EGFR exon 20 insertion mutation non-small cell lung cancer (NSCLC).
Read more →CGEMZipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics announced that their Phase 3 REZILIENT3 trial has successfully met its primary endpoint of progression-free survival. This trial evaluates the efficacy of zipalertinib in combination with chemotherapy for patients with EGFR Exon 20 insertion mutation non-small cell lung cancer. The results from this interim analysis are promising for future treatment options.
Read more →CGEMCullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Cullinan Therapeutics provided a corporate update highlighting promising data for its T cell engagers CLN-978 and velinotamig, with plans for Phase 2 studies in 2027. The company reported a net loss of $53.7 million for Q2 2026 but maintains a strong cash position of $356 million, ensuring operational runway into 2029. Upcoming data presentations are expected to further inform the clinical potential of their therapies.
Read more →CGEMCullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML
Cullinan Therapeutics announced positive feedback from the FDA regarding its CLN-049 program during an End-of-Phase 1 meeting. The company plans to initiate a potentially registrational Phase 2 study for CLN-049 in patients with relapsed/refractory acute myeloid leukemia (AML) in Q3 2026. The FDA's feedback supports the development strategy and highlights the urgent need for new treatments in this area.
Read more →CGEM▼ -8.6%on this news
Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases
Cullinan Therapeutics has reported promising clinical data for its T cell engager programs, CLN-978 and velinotamig, targeting autoimmune diseases like systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The data indicates significant efficacy, including clinical remissions and renal responses in patients. The company plans to expand its clinical trials and present further data in the coming months.
Read more →CGEMCullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress
Cullinan Therapeutics presented initial clinical data for CLN-978, a CD19xCD3 T cell engager, at the EULAR 2026 Congress. The data indicates significant clinical benefits, including remissions in patients with systemic lupus erythematosus and rheumatoid arthritis following treatment. Alongside a favorable safety profile and substantial B cell depletion, the data support CLN-978’s potential as a novel therapeutic option. Further studies are planned to advance the development of CLN-978 for these challenging-to-treat autoimmune conditions.
Read more →CGEM▲ +11.7%on this news
Cullinan Therapeutics to Host Immunology Day to Showcase Promising Initial Clinical Data in Autoimmune Diseases for CLN-978, a CD19 T Cell Engager, and Velinotamig, a BCMA T Cell Engager
Cullinan Therapeutics will host an Immunology Day event on June 10, 2026, in New York City to present new clinical data for its autoimmune disease therapies, CLN-978 and Velinotamig. Initial results from over 30 patients involved in systemic lupus erythematosus and rheumatoid arthritis studies will be shared. The event is aimed at analysts and institutional investors, featuring discussions led by prominent clinical experts. The company aims to provide insights into data milestones and its global development strategy.
Read more →CGEMCullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia
Cullinan Therapeutics has received FDA Orphan Drug Designation for CLN-049, a novel FLT3xCD3 T cell engager, aimed at treating relapsed/refractory acute myeloid leukemia (AML). This designation underscores the urgent need for new therapies in AML, particularly for patients with TP53 mutations. CLN-049 is currently being evaluated in ongoing Phase 1 clinical trials.
Read more →CGEM▼ -5.5%on this newsshared move
Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress
Cullinan Therapeutics announced the presentation of initial clinical data for CLN-978 at the EULAR 2026 Congress. The data, from ongoing Phase 1 studies, indicates a favorable safety profile and early signs of clinical activity in patients with treatment-refractory rheumatoid arthritis and systemic lupus erythematosus. The findings will be shared in detail during the congress in London.
Read more →CGEMCullinan Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
Cullinan Therapeutics provided a corporate update and reported its Q1 2026 financial results. The company announced initial clinical data for its CD19 T cell engager, CLN-978, to be presented at the EULAR 2026 Congress. Additionally, the FDA accepted the NDA for zipalertinib, with a target action date of February 27, 2027. Cullinan's financial position remains strong, with cash reserves expected to last into 2029.
Read more →CGEMU.S. Food and Drug Administration Accepts New Drug Application for Zipalertinib for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
The FDA has accepted a New Drug Application for zipalertinib, a treatment for locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations. This acceptance is based on positive results from the Phase 2b REZILIENT1 clinical trial, which demonstrated a 35% objective response rate. The PDUFA target action date is set for February 27, 2027.
Read more →CGEMCullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Cullinan Therapeutics has announced its fourth quarter and full year 2025 financial results alongside several key updates. Initial clinical data for their therapy CLN-978 for systemic lupus erythematosus and rheumatoid arthritis is slated for release in Q2 2026. Furthermore, the company has completed its rolling NDA submission for zipalertinib, with expectations for significant data releases throughout 2026. Despite a growing cash position of $439 million, the company reported increasing net losses and R&D expenses, highlighting both potential progress and financial challenges.
Read more →CGEMCullinan Therapeutics to Participate in Upcoming Investor Conferences
Cullinan Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in upcoming investor conferences. The company focuses on developing first- or best-in-class therapies for autoimmune diseases and cancer. Webcasts of the events will be available on their investor relations website, showcasing their commitment to innovation in healthcare.
Read more →About Cullinan Therapeutics, Inc.
HeadquartersONE MAIN STREET, CAMBRIDGE, MA, 02142
BIOPHARMAWATCH ELITE PLUS
Trade the next CGEM catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime